Eurofins targets 6.5% organic growth through 2027 with margin optimization
Q4 2024 Management View CEO Gilles Martin highlighted significant progress in the company's hub-and-spoke lab network and IT infrastructure, with a focus on economies of scale and digitalization. He ...
The Noise Has Been Loud Lately, But At The Deepest Level Eurofins Is Unchanged
We believe Eurofins Scientific shares represent compelling value, and we added modestly to our investment in the fourth quarter. Click here to read more.
Seeking Alpha14d
Eurofins Scientific SE (ERFSF) Q4 2024 Earnings Call Transcript
Normally, biopharma is almost a double digit business ... we have a specific situation now is that the best investment for Eurofins now is to buy back its own shares. And whatever the ...
Business Wire15d
Eurofins Achieves New Record Level of Annual Revenues While Demonstrating a Strong Increase in Margins and Cash Generation and Returns to Its Pre-COVID Profitability and Cash ...
Eurofins (Paris:ERF) pre-publishes below its preliminary unaudited 2024 consolidated financial results for the year ending 31 Decembe ...
Investing15d
Earnings call transcript: Eurofins sees strong Q4 2024 growth, profits up 32%
Eurofins is optimistic about its future prospects, aiming for a 24% EBITDA margin by 2027. The company expects the biopharma segment to normalize and return to growth, with mid-single-digit ...
Eurofins Scientific SE (ERFSF) Full Year 2024 Earnings Call Highlights: Strong Revenue Growth ...
Eurofins Scientific SE (ERFSF) reports robust financial performance with significant investments in digitalization, despite facing headwinds in key segments.